In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
The companies have expanded their agreement to include evaluating tazemetostat and atezolizumab in non-small cell lung cancer
 
Takeda and Seattle Genetics announce positive results from Phase 3 ECHELON-1 trial evaluating Adcetris in frontline advanced Hodgkin's lymphoma
 
Application is based on clinical trial results from the Phase 3 ALCANZA and Phase 2 investigator-sponsored studies in cutaneous T cell lymphoma
 
Metabolomics shifts from map-making to therapeutic strategizing
 
Earlier-stage cancer programs remain a mainstay of American Association for Cancer Research (AACR) annual meeting generally, but immuno-oncology approaches stand out
 
Trial combines Regeneron’s PD-1 inhibitor and Inovio’s T cell and immune activators in glioblastoma multiforme
 
Immunovaccine, Idera and Sunesis all share preclinical research results at AACR 2017
 
FDA’s approval of Merck & Co.’s pembrolizumab marks a watershed moment, heralding the possible era of 'tumor-agnostic' drug approvals
 
 
FEATURES
 
 
DDNews checks in on the growing and promising activity around immuno-oncology
 
OPINION
by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

by Laurie Heilmann
As the design of anticancer agents has evolved, the processes, methods and equipment used to aid the fight against cancer have too, leading to the resurgence of immunotherapy as a powerful way of fighting cancer


 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.